Primary Screen Case Study

At Pelago Bioscience, we offer a high-throughput screening service based on CETSA® – a transformative, label-free assay for target engagement quantification in physiologically relevant contexts.

This case study illustrates how employing high-throughput screening with CETSA can deliver actionable data and result in significant time savings compared to other approaches.

Astra Zeneca Case Study - Pelago_1

Witness how AstraZeneca screened 500,000 compounds on a protein target, achieving superior hit rates and saving six months in the process.

Speak to our experts

Ready to streamline your screening processes and accelerate your drug discovery timeline?